Gulf Pharmaceutical Industries (JULPHAR) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

With a growth in Net Sales of 12.96%, the company declared Very Positive results in Jun 25

The company has declared positive results for the last 4 consecutive quarters
OPERATING CASH FLOW(Y) Highest at AED 145.7 MM
ROCE(HY) Highest at 6.2%
INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost

With ROE of 2.04%, it has a expensive valuation with a 2.00 Price to Book Value

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

AED 1,409 Million (Micro Cap)

P/E

28.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.01

Return on Equity

5.76%

Price to Book

1.47

Revenue and Profits:

Net Sales:

348 Million

(Quarterly Results - Jun 2025)

Net Profit:

17 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-6.82%

6 Months

-7.52%

1 Year

-5.38%

2 Years

63.35%

3 Years

6.96%

4 Years

-34.22%

5 Years

-15.17%

Gulf Pharmaceutical Industries for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Gulf Pharmaceutical Industries Reports Mixed Financial Results Amidst Growth in Key Metrics

Gulf Pharmaceutical Industries, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial performance for the quarter ending June 2025. The results indicate a challenging financial landscape, with very negative overall performance noted for the period.

Despite the overall negative performance, several key metrics show promising growth. The operating cash flow reached its highest level at AED 145.7 MM, indicating strong liquidity management. Additionally, the return on capital employed (ROCE) for the half-year stands at 6.2%, reflecting effective utilization of capital.

One notable aspect of Gulf Pharmaceutical Industries' financials is its interest coverage ratio, which suggests that the company has minimal interest costs. This positions the company favorably in terms of financial stability. Furthermore, the raw...

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

24.78%

EBIT Growth (5y)

16.91%

EBIT to Interest (avg)

-2.30

Debt to EBITDA (avg)

73.60

Net Debt to Equity (avg)

0.03

Sales to Capital Employed (avg)

0.86

Tax Ratio

10.72%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

1.26%

ROE (avg)

0.76%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.61

EV to EBIT

22.25

EV to EBITDA

11.29

EV to Capital Employed

1.60

EV to Sales

1.36

PEG Ratio

0.14

Dividend Yield

ROCE (Latest)

7.20%

ROE (Latest)

5.76%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

Bearish

No Signal

Bollinger Bands

Bearish

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -3.09% vs 2,820.33% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -22.12% vs -7.26% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "348.10",
          "val2": "359.20",
          "chgp": "-3.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "39.50",
          "val2": "47.80",
          "chgp": "-17.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "7.60",
          "val2": "15.20",
          "chgp": "-50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "16.90",
          "val2": "21.70",
          "chgp": "-22.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "68.70%",
          "val2": "89.90%",
          "chgp": "-2.12%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 2.74% vs -20.95% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 121.48% vs -184.27% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,312.50",
          "val2": "1,277.50",
          "chgp": "2.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "63.10",
          "val2": "-33.20",
          "chgp": "290.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "62.20",
          "val2": "56.30",
          "chgp": "10.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "16.30",
          "val2": "-75.90",
          "chgp": "121.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "48.10%",
          "val2": "-26.00%",
          "chgp": "7.41%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

348.10

359.20

-3.09%

Operating Profit (PBDIT) excl Other Income

39.50

47.80

-17.36%

Interest

7.60

15.20

-50.00%

Exceptional Items

0.00

Consolidate Net Profit

16.90

21.70

-22.12%

Operating Profit Margin (Excl OI)

68.70%

89.90%

-2.12%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -3.09% vs 2,820.33% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -22.12% vs -7.26% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

1,312.50

1,277.50

2.74%

Operating Profit (PBDIT) excl Other Income

63.10

-33.20

290.06%

Interest

62.20

56.30

10.48%

Exceptional Items

0.00

Consolidate Net Profit

16.30

-75.90

121.48%

Operating Profit Margin (Excl OI)

48.10%

-26.00%

7.41%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 2.74% vs -20.95% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 121.48% vs -184.27% in Dec 2023

All Annual Results

Company CV

About Gulf Pharmaceutical Industries

Gulf Pharmaceutical Industries

Pharmaceuticals & Biotechnology

Gulf Pharmaceutical Industries PSC (Julphar) is a United Arab Emirates-based public shareholding company engaged in manufacturing and selling of medicines, drugs and other types of pharmaceutical and medical compounds, in addition to cosmetic compounds. The Company maintains a range of product portfolio, which target major therapeutic segments, including endocrinology, anti-infective, cardiovascular and gastroenterology, over-the-counter, nephrology, dermatology, respiratory, metabolic and burn and wound management. The Company operates through a network of more than 10 manufacturing plants, and a logistics network. The Company has approximately 800 products in various dosage forms, and more in the pipeline. The Company’s subsidiaries include Mena Cool FZE, which is engaged in the transportation, and Julphar Pharmaceuticals PLC, which is engaged in Manufacturing of medicines, wrapping and packing materials.

Company Coordinates

Company Details

Digdaga Airport Road, P.O.Box 997 RAS AL KHAIMAH CITY None : None

Tel: 971 7 2461461971 7 2045273

http://www.julphar.net

Registrar Details

Gulf Pharmaceutical Industries

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

With a growth in Net Sales of 12.96%, the company declared Very Positive results in Jun 25

With ROE of 2.04%, it has a expensive valuation with a 2.00 Price to Book Value

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Gulf Pharmaceutical Industries Reports Mixed Financial Results Amidst Growth in Key Metrics

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Gulf Pharmaceutical Industries

Company Coordinates